Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease

Inflammatory Bowel Diseases

Volumn 12, Issue 9, 2006, Pages 831-836

  Jaspers, Gerald J ^a   Verkade, Henkjan J ^a   Escher, Johanna C ^b   De Ridder, Lissy ^c   Taminiau, Jan A J M ^c   Rings, Edmond H H M ^a,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Azathioprine; Corticosteroids; Crohn's disease; Pediatric; Remission

Indexed keywords

AMINOSALICYLIC ACID; AMYLASE; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADOLESCENT; AMYLASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; ELECTIVE SURGERY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PANCREATITIS; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; AZATHIOPRINE; CHILD; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 33748460486     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.mib.0000232470.00703.67     Document Type: Article

References (24)

1. Escher JC, Taminiau JA, Nieuwenhuis EE, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34-58.
2. Markowitz J, Grancher K, Kohn N, et al. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol. 2002;97:928-932.
3. Levine A, Milo T, Buller H, et al. Consensus and controversy in the management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr. 2003;36:464-469.
4. Murch SH, Baldassano R, Buller H, et al. Inflammatory bowel disease: working group report of the second world congress of pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr. 2004;39(Suppl 2):S647-S654.
5. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
6. Barabino A, Torrente F, Ventura A, et al. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther. 2002;16:1125-1130.
7. Fuentes D, Torrente F, Keady S, et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:913-921.
8. Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol. 2000;30:294-298.
9. Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. Rev Gastroenterol Disord. 2003;3:S23-S29.
10. Ramakrishna J, Langhans N, Calenda K, et al. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1996;22:296-302.
11. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr. 1990;117:809-814.
12. Buller H, Chin S, Kirschner B, et al. Inflammatory bowel disease in children and adolescents: working group report of the first world congress of pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr. 2002;35(Suppl 2):S151-S158.
13. Zaag-Loonen HJ, Casparie M, Taminiau JA, et al. The incidence of pediatric inflammatory bowel disease in the Netherlands: 1999-2001. J Pediatr Gastroenterol Nutr. 2004;38:302-307.
14. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
15. Loonen HJ, Griffiths AM, Merkus MP, et al. A critical assessment of items on the pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 2003;36:90-95.
16. Shepanski MA, Markowitz JE, Mamula P, et al. Is an abbreviated pediatric Crohn's disease activity index better than the original? J Pediatr Gastroenterol Nutr. 2004;39:68-72.
17. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
18. Kundhal PS, Critch JN, Zachos M, et al. Pediatric Crohn disease activity index: responsive to short-term change. J Pediatr Gastroenterol Nutr. 2003;36:83-89.
19. Hanauer S, Sandborn WJ, Persson A, et al. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:363-371.
20. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996;39:82-86.
21. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-266.
22. Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003;17:131-137.
23. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology. 1998;115:813-821.
24. Sawczenko A, Lynn R, Sandhu BK. Variations in initial assessment and management of inflammatory bowel disease across Great Britain and Ireland. Arch Dis Child. 2003;88:990-994.